Advertisement
Singapore markets close in 7 hours 7 minutes

  • Straits Times Index

    3,305.71
    +8.82 (+0.27%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,539.35
    +332.22 (+1.82%)
     

  • FTSE 100

    8,172.15
    +50.91 (+0.63%)
     

  • Bitcoin USD

    59,328.98
    +2,054.26 (+3.59%)
     

  • CMC Crypto 200

    1,282.29
    +11.55 (+0.91%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • Dow

    38,225.66
    +322.37 (+0.85%)
     

  • Nasdaq

    15,840.96
    +235.48 (+1.51%)
     

  • Gold

    2,313.00
    +3.40 (+0.15%)
     

  • Crude Oil

    79.14
    +0.19 (+0.24%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,588.37
    +8.07 (+0.51%)
     

  • Jakarta Composite Index

    7,117.42
    -7,234.20 (-50.41%)
     

  • PSE Index

    6,657.10
    +10.55 (+0.16%)
     

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

scPharmaceuticals, Inc.
·1-min read
scPharmaceuticals, Inc.
scPharmaceuticals, Inc.

Management to host conference call and webcast at 4:30 p.m. ET

BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss the financial results for the fourth quarter and full-year 2023 and provide a business update.

Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13744172.

ADVERTISEMENT

To access the new Call me™ feature, which avoids having to wait for an operator, click here.

The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com